Iguratimod plus low-dose rituximab for hard-to-treat ITP
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests whether adding iguratimod (a medicine that helps control immune system activity) to a low dose of rituximab (a targeted therapy for immune cells) works better than low-dose rituximab alone for people with ITP that has not responded to steroid treatment or that comes back after steroids are stopped.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have ITP that has been confirmed by your doctor, and other causes of low platelets have been ruled out.
- Your platelet count is less than 30 × 10⁹/L at the time you enter the study.
- You did not get a lasting response to at least 4 weeks of full-dose steroids, or your platelets came back while tapering steroids or after stopping them.
- You have not received rituximab before.
- You do not have other conditions that cause secondary ITP, such as HIV, hepatitis C, H. pylori infection, or lupus.
- You are not pregnant or nursing, and you do not have severe heart problems, active cancer, or abnormal liver/kidney function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immunotherapy called CAR-T cells that target two proteins (CD19 and BCMA) on immune cells. It is for adults with severe ITP that has not improved with other treatments. The goal is to reset the immune system to stop attacking platelets.
This trial tests whether adding an anti-CD38 antibody to the standard drug rituximab works better than rituximab alone for adults with long-term immune thrombocytopenia (ITP) who have already tried steroids without lasting success.
This trial tests a new antibody drug (anti-CD38) compared to a standard drug (rituximab) for adults with ITP that hasn't responded well to steroids. The goal is to see if the new drug works better at raising platelet counts and reducing bleeding risk.
This trial compares two treatment approaches for adults with primary immune thrombocytopenia (ITP), a condition where platelet counts are too low. It looks at whether adding rituximab to eltrombopag helps control ITP better and more safely.
This trial tests a combination of two common medicines (atorvastatin and NAC) plus romiplostim to treat ITP when steroids have stopped working or stopped working. It may help raise your platelet counts.
This trial tests whether adding a new drug (telitacicept) to a standard platelet booster (eltrombopag) works better than eltrombopag alone for adults whose ITP has not responded to steroids.
Hear when a new Immune Thrombocytopenia (ITP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.